Tech giant Apple has confirmed - in a recent statement to TechCrunch - that it has acquired BookLamp --- the Boise, Idaho-based start-up which, through its Book Genome Project, makes recommendations to readers on the basis of unique algorithms that integrate search titles.
Despite the fact that Apple has not made any disclosure about the price it paid for acquiring BookLamp, TechCrunch has revealed that the company apparently paid up to $15 million for acquiring BookLamp and its 10 employees.
Though Apple's BookLamp purchase has been confirmed to TechCrunch recently, the acquisition actually took place in April this year, when BookLamp had announced in a statement published on its website that it was shutting down. The startup had not given any reason its immediate close.
The evident objective behind Apple's decision to acquire BookLamp is to bring about an improvement in its iBooks service, as well as to enable readers find more book titles in accordance with their interests.
However, Apple itself is yet to officially divulge its end-game with BookLamp, though the toolsets offered by the startup can unfold a number of possibilities from advertising options, tailored book "Playlists" and smart recommendations.
In its annual Environmental Responsibility Report for fiscal year 2015 released last Thursday, tech giant Apple has revealed that nearly 90 million pounds of unwanted or broken electronics were processed by the company over the last one year....
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
There are a lot of things not going right at the IRS and...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).